Gabriel Garcia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gabriel Garcia has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Aijaz Ahmed
Division of Gastroenterology and Hepatology Stanford University School of Medicine Stanford California USA
13 shared publications - Mindie H. Nguyen
Division of Gastroenterology and Hepatology Department of Medicine Stanford University Medical Center Palo Alto California USA
13 shared publications - Emmet B. Keeffe
Stanford University Medical Center
7 shared publications - Huy A. Nguyen
San Jose Gastroenterology
7 shared publications - Huy N. Trinh
Pacific Health Foundation
7 shared publications - Mindie H. Nguyen
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, 750 Welch Road, Suite 210, Palo Alto, CA 94304-1509, USA
7 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-1130-1130
Sa1488 - Adherence to Aasld Treatment Guidelines on Treatment Initiation Among Treatment-Eligible Patients with Chronic Hepatitis B: Experiences from Primary Care and Referral Practices
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-1130-1130
Sa1488 - Adherence to Aasld Treatment Guidelines on Treatment Initiation Among Treatment-Eligible Patients with Chronic Hepatitis B: Experiences from Primary Care and Referral Practices
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1166
Higher Rates of Cirrhosis, Hepatic Decompensation, and Hepatocellular Carcinoma (HCC) in Asian and Hispanic Patients with Hepatitis C (HCV) Infection Compared to White and Black Ethnicity Regardless of Gender Differences: A Single Center Retrospective Cohort Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1166
Higher Rates of Cirrhosis, Hepatic Decompensation, and Hepatocellular Carcinoma (HCC) in Asian and Hispanic Patients with Hepatitis C (HCV) Infection Compared to White and Black Ethnicity Regardless of Gender Differences: A Single Center Retrospective Cohort Study
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1132
Mo1499 Sex Differences in Disease Presentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma (HCC)
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1132
Mo1499 Sex Differences in Disease Presentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma (HCC)
- 27 November 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 59 (1) , 192-200
Clinical Presentation and Survival of Asian and Non-Asian Patients with HCV-Related Hepatocellular Carcinoma
Hepatitis C virus (HCV) is an important cause of hepatocellular carcinoma (HCC) in Asians; however, it is often overlooked due to the high prevalence of hepatitis B virus in Asians. This study examines HCV-related HCC in Asians. We conducted a retrospective cohort study of 792 consecutive Asian (n = 220) and non-Asian (n = 572) patients with HCV-related HCC identified at Stanford University Medical Center using International Classification of Diseases-9 diagnosis between July 1996 and June 2012. Asian patients were much older [66 (38–88) vs. 56 (31–87) years, P P P = 0.001). Asian patients were more likely to undergo palliative therapy (46 vs. 28 %) and less likely to be listed for liver transplantation (20 vs. 48 %, P P = 0.16). Overall, there was a trend for higher median survival rates in Asians (30 vs. 21 months, P = 0.091). Asians had higher long-term survival with palliative therapy only (5-year survival: 28 vs. 10 %, P There were distinct differences in clinical presentations of Asian and non-Asian patients with HCV-related HCC. Asians with HCV-related HCC are less likely to undergo liver transplantation and more likely to have delayed HCV diagnosis. Improved strategies in HCV screening in Asians are needed, as it may lead to earlier diagnosis and treatment of HCV infection and possible prevention of HCC development.
- 27 November 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 59 (1) , 192-200
Clinical Presentation and Survival of Asian and Non-Asian Patients with HCV-Related Hepatocellular Carcinoma
Hepatitis C virus (HCV) is an important cause of hepatocellular carcinoma (HCC) in Asians; however, it is often overlooked due to the high prevalence of hepatitis B virus in Asians. This study examines HCV-related HCC in Asians. We conducted a retrospective cohort study of 792 consecutive Asian (n = 220) and non-Asian (n = 572) patients with HCV-related HCC identified at Stanford University Medical Center using International Classification of Diseases-9 diagnosis between July 1996 and June 2012. Asian patients were much older [66 (38–88) vs. 56 (31–87) years, P P P = 0.001). Asian patients were more likely to undergo palliative therapy (46 vs. 28 %) and less likely to be listed for liver transplantation (20 vs. 48 %, P P = 0.16). Overall, there was a trend for higher median survival rates in Asians (30 vs. 21 months, P = 0.091). Asians had higher long-term survival with palliative therapy only (5-year survival: 28 vs. 10 %, P There were distinct differences in clinical presentations of Asian and non-Asian patients with HCV-related HCC. Asians with HCV-related HCC are less likely to undergo liver transplantation and more likely to have delayed HCV diagnosis. Improved strategies in HCV screening in Asians are needed, as it may lead to earlier diagnosis and treatment of HCV infection and possible prevention of HCC development.
- 27 November 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 59 (1) , 183-191
Primary Surgical Resection Versus Liver Transplantation for Transplant-Eligible Hepatocellular Carcinoma Patients
Hepatocellular carcinoma (HCC) is a leading cause of mortality worldwide. Existing studies comparing outcomes after liver transplantation (LT) versus surgical resection among transplant-eligible patients are conflicting. The purpose of this study was to compare long-term survival between consecutive transplant-eligible HCC patients treated with resection versus LT. The present retrospective matched case cohort study compares long-term survival outcomes between consecutive transplant-eligible HCC patients treated with resection versus LT using intention-to-treat (ITT) and as-treated models. Resection patients were matched to LT patients by age, sex, and etiology of HCC in a 1:2 ratio. The study included 171 patients (57 resection and 114 LT). Resection patients had greater post-treatment tumor recurrence (43.9 vs. 12.9 %, p < 0.001) compared to LT patients. In the as-treated model of the pre-model for end stage liver disease (MELD) era, LT patients had significantly better 5-year survival compared to resection patients (100 vs. 69.5 %, p = 0.04), but no difference was seen in the ITT model. In the multivariate Cox proportional hazards model, inclusive of age, sex, ethnicity, tumor stage, and MELD era (pre-MELD vs. post-MELD), treatment with resection was an independent predictor of poorer survival (HR 2.72; 95 % CI, 1.08–6.86). Transplant-eligible HCC patients who received LT had significantly better survival than those treated with resection, suggesting that patients who can successfully remain on LT listing and actually undergo LT have better outcomes.
- 27 November 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 59 (1) , 183-191
Primary Surgical Resection Versus Liver Transplantation for Transplant-Eligible Hepatocellular Carcinoma Patients
Hepatocellular carcinoma (HCC) is a leading cause of mortality worldwide. Existing studies comparing outcomes after liver transplantation (LT) versus surgical resection among transplant-eligible patients are conflicting. The purpose of this study was to compare long-term survival between consecutive transplant-eligible HCC patients treated with resection versus LT. The present retrospective matched case cohort study compares long-term survival outcomes between consecutive transplant-eligible HCC patients treated with resection versus LT using intention-to-treat (ITT) and as-treated models. Resection patients were matched to LT patients by age, sex, and etiology of HCC in a 1:2 ratio. The study included 171 patients (57 resection and 114 LT). Resection patients had greater post-treatment tumor recurrence (43.9 vs. 12.9 %, p < 0.001) compared to LT patients. In the as-treated model of the pre-model for end stage liver disease (MELD) era, LT patients had significantly better 5-year survival compared to resection patients (100 vs. 69.5 %, p = 0.04), but no difference was seen in the ITT model. In the multivariate Cox proportional hazards model, inclusive of age, sex, ethnicity, tumor stage, and MELD era (pre-MELD vs. post-MELD), treatment with resection was an independent predictor of poorer survival (HR 2.72; 95 % CI, 1.08–6.86). Transplant-eligible HCC patients who received LT had significantly better survival than those treated with resection, suggesting that patients who can successfully remain on LT listing and actually undergo LT have better outcomes.